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Abstract
Background and aims—Inhibition of
glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) by nitric oxide (NO) in
intestinal preconditioning could modify
the rate of formation of glycolytic inter-
mediates. Fructose-1,6-biphosphate
(F16BP) is a glycolytic intermediate that
protects tissue from ischaemia/
reperfusion injury. We evaluated if F16BP
may be endogenously accumulated as a
consequence of GAPDH inhibition by NO
during intestinal preconditioning in rats.
Methods—We assessed: (1) eVect of pre-
conditioning on F16BP content; (2) eVect
of NO on GAPDH activity before and dur-
ing sustained ischaemia; and (3) protec-
tive eVect of F16BP in control, ischaemic,
and preconditioned animals with or with-
out administration of N-nitro-L-arginine
methyl ester (L-NAME), NO donor, or
F16BP.
Results—Preconditioned rats showed a
significant transient decrease in GAPDH
activity and also maintained basal F16BP
levels longer than ischaemic rats.
L-NAME administration to precondi-
tioned rats reversed these eVects. F16BP
administration to ischaemic rats de-
creased protein release in the perfusate.
Administration of F16BP to L-NAME
treated rats attenuated the harmful eVect
of L-NAME.
Conclusions—Our study indicates that
F16BP may be endogenously accumulated
in preconditioned rats as a consequence of
inhibition of GAPDH by NO, and this may
contribute to the protection observed in
intestinal preconditioning.
(Gut 2001;48:168–175)
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Ischaemia/reperfusion (I/R) syndrome is one of
the most important problems in the primary
non-function associated with transplantation
procedures. Preconditioning is a phenomenon
defined as one or more brief periods of ischae-
mia with intermittent reperfusion that can pro-
tect the organ against the subsequent sustained
I/R injury.1 2 The protective eVect of precondi-
tioning was first proposed in the heart and the
technique has since been applied to other
tissues such as endothelium, brain, skeletal
muscle, skin, liver, and the small intestine.3–5
For these reasons, it seems clear that precondi-
tioning could, in the future, be successfully
applied in diVerent types of transplantation.
Although preconditioning was first de-
scribed more than a decade ago, the mecha-
nisms underlying its protective eVect are not
fully understood. Nitric oxide (NO) is one of
the mediators that has been most widely stud-
ied in this process. In the small intestine, previ-
ous studies have demonstrated an increase in
NO synthesis after preconditioning.2 Blocking
of endogenous production of NO may inhibit
part of the protection induced by this process.
Moreover, other studies have suggested that
NO may be an important protective molecule
against intestinal I/R injury.3–6 These data
clearly suggest that NO may be useful as a
therapeutic agent in minimising the dysfunc-
tion at the onset of I/R.
In addition to its protective role, NO also has
a metabolic eVect.7 It can inhibit the glycolytic
enzyme glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) through a rapid event such
as S-nitrosylation of thiol groups present in the
molecule8 or by ADP ribosylation,9 which
changes the number of thiol groups. Our previ-
ous studies have shown that this critical step in
glycolysis appears to be reversibly inactivated
by NO generated during intestinal precondi-
tioning.10
Fructose 1,6-biphosphate (F16BP), a high
energy glycolytic intermediate, has been shown
to be therapeutically eVective in shock, ischae-
mia, and post-ischaemic reperfusion injury in
diVerent organs.11–13 Several authors have asso-
ciated the protective role of exogenous admin-
istration of F16BP, observed in a wide variety
of organ and cell injuries, with the prevention
of intracellular ATP depletion.14 15 In the case
of intestinal I/R, it has been shown that admin-
istration of F16BP could enhance energy
production from carbohydrates, thereby at-
tenuating ischaemic damage and accelerating
regeneration of intestinal villi after reper-
fusion.16
There are several protective eVects of F16BP
that are independent of the tissue or experi-
mental model used. An exogenous supply of
F16BP can inhibit neutrophil free radical pro-
duction,17 maintain the correct XDH/XO
ratio,18 prevent changes in intracellular cal-
cium,19 increase peristaltic activity,16 and im-
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prove the eYcacy of preservation solutions in
renal transplantation.20
In the glycolysis pathway, the formation rate
of a glycolytic intermediate (among them
F16BP) can be modified by inhibition of any
glycolytic enzyme. The fact that NO generated
during preconditioning inhibits the enzyme
GAPDH10 could lead to NO dependent F16BP
accumulation. Moreover, this could be a new
protective mechanism before I/R injury, possi-
bly due to the action of the known endogenous
protector F16BP.
Hence the first objective of this study was to
determine if preconditioning can modify the
production of F16BP via the glycolysis path-
way. The second objective was to determine if
this modification was caused by NO dependent
GAPDH inhibition produced during precondi-
tioning. The third objective was to assess the
protective eVect of F16BP on intestinal pre-
conditioning. For this purpose, we determined
F16BP, glucose content, and GAPDH activity
in the small intestine of rats subjected to intes-
tinal preconditioning with or without NO. The
eVect of F16BP administration was also evalu-
ated.
Material and methods
The study was performed using male Wistar
rats (Ifa Credo, Barcelona, Spain) weighing
250–300 g. Animals were fasted for 12 hours
before surgery, anaesthetised with urethane
10% (10 mg/kg intraperitoneally), and placed
in the supine position, with body temperature
maintained at 36–37°C. The abdominal area
was covered with saline soaked gauze at 37°C
and a plastic cover to minimise dehydration of
exposed tissues.
The experiment was conducted under the
supervision of our institution’s research com-
mission and followed EU guidelines for the
handling and care of laboratory animals.
INTESTINAL ISCHAEMIC PRECONDITIONING
To induce intestinal ischaemic precondition-
ing, a laparotomy was performed and the supe-
rior mesenteric artery was exposed and oc-
cluded for 10 minutes using an atraumatic
arterial clamp followed by 10 minutes of reper-
fusion.
EXPERIMENTAL GROUPS
EVect of preconditioning on F16BP and glucose
content during the ischaemic period.
To evaluate the eVect of preconditioning and
its relationship with NO on F16BP and glucose
content over a range of ischaemic periods, the
following groups of animals (n=8) were
studied.
Group I—Control. Animals were subjected to
anaesthesia and laparotomy.
Group II—Control+L-NAME (C+NAME). As
for group I but with previous administration of
N-nitro-L-arginine methyl ester (L-NAME 10
mg/kg) by direct puncture into the inferior
cava.
Group III—Ischaemia (I). Four subgroups of
eight animals, where each group was subjected
to diVerent periods of ischaemia (2, 30, or 90
minutes).
Group IV—Ischaemia+spermine NONOate
(I+NONOS). Animals underwent the same
procedure as in group III but with previous
intravenous administration of the NO donor
spermine NONOate (NONOS 10 mg/kg
resuspended in phosphate buVered saline,
pH=7.4, 30 minutes before administration) by
direct puncture into the inferior cava.2
Group V—Preconditioning group (Prec+I). As
for group III (ischaemia) but with previous
preconditioning, as described above in all ani-
mals.
Group VI—Preconditioning+L-NAME (Prec+I
+NAME). As for group V but with previous
administration of L-NAME (10 mg/kg) by
direct puncture into the inferior cava, five min-
utes before the beginning of the precondition-
ing process. Previous studies have shown that
this dose and the preincubation conditions of
the NO inhibitor are eVective.2 10
After each sustained ischaemic period (2, 30,
or 90 minutes), tissue samples were obtained,
immediately frozen, and maintained at −80°C
for biochemical analysis.
EVect of NO on GAPDH activity before and
during sustained ischaemia
To study the eVect of the preconditioning
period on GAPDH activity and its relationship
with NO generation, the following animals
(n=8 each group) were added to the above
groups.
Group VII—Preconditioning (P). Animals were
subjected to 10 minutes of ischaemia followed
by 10 minutes of reperfusion.
Group VIII—Preconditioning+L-NAME (P+
NAME). As for group VII but with previous
administration of L-NAME (10 mg/kg) by
direct puncture into the inferior cava, five min-
utes before the beginning of the precondition-
ing process.
Group IX—Preconditioning+iNOS inhibitor
(P+1400W). As for group VII but with
previous administration of the inducible nitric
oxide synthase (iNOS) inhibitor 1400W (N-(3-
(aminomethyl)benzyl) acetamide) (3 mg/kg
subcutaneously, dissolved in 500 µl of saline)
40 minutes before the beginning of the precon-
ditioning process. This dose has been proved to
be eVective in rats.21
Tissue samples from groups I–IX were
obtained, immediately frozen, and maintained
at −80°C until analytical determination of
GAPDH activity and NO generation.
Role of F16BP on intestinal preconditioning
To assess the protective eVect of F16BP on
intestinal preconditioning by measuring pro-
tein release in the intestinal lumen, the follow-
ing protocol was performed. After laparotomy,
proximal and distal portions of the small bowel
of each rat were cannulated and secured with
5-0 silk ligatures and continuously perfused
with saline solution (100 ml/h) at 37°C.
Animals were divided into the following groups
(n=8).
Group X— Control. Animals were subjected to
anaesthesia and laparotomy for 120 minutes.
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Group XI—Ischaemia/reperfusion (I/R). Ani-
mals were subjected to 90 minutes of ischaemia
followed by 30 minutes of reperfusion.
Group XII—Ischaemia/reperfusion+F16BP
(I/R+F16BP). As for group XI but with super-
fusion over the small intestine of 5 mM of
F16BP throughout the process (a dose proved
to be eVective in previous studies).17
Group XIII—Ischaemia/reperfusion+spermine
NONOate (I/R+NONOS). Animals under-
went the same procedure as group XI but with
previous intravenous administration of the NO
donor spermine NONOate (10 mg/kg resus-
pended in phosphate buVered saline, pH=7.4,
30 minutes before administration) by direct
puncture into the inferior cava.2
Group XIV—Preconditioning (P+I/R). As for
group XI (I/R) but with previous precondition-
ing, as described above.
Group XV—Preconditioning+L-NAME (P+
N+I/R). As for group XIV but with previous
administration of L-NAME (10 mg/kg) by
direct puncture into the inferior cava, five min-
utes before the beginning of the precondition-
ing process.
Group XVI—Preconditioning+L-NAME+
F16BP (P+N+I/R+F16BP). As for group XV
but with superfusion over the small intestine of
5 mM of F16BP throughout the process.
Samples of intestinal perfusate were col-
lected after 0, 30, and 90 minutes of ischaemia,
and at five and 30 minutes after reperfusion.
To directly address F16BP incorporation in
the intestine, we performed an additional
experiment. We added F16BP (5 mM) by
superfusion over the small intestine to a group
of animals subjected to 90 minutes of ischae-
mia. In this case, mesentery as well as intestinal
samples were obtained at the end of the proto-
col to measure F16BP levels.
BIOCHEMICAL ANALYSIS
F16BP concentration
To evaluate F16BP content, tissue samples
were homogenised in ice cold perchloric acid
0.6 mmol/l. The homogenate was centrifuged
at 10 000 g for 30 minutes. The supernatant
was neutralised with potassium carbonate
solution to a pH of 3.5–4.5. The assay mixture
consisted of a triethanol amine buVer (pH 7.6),
5 mmol/l NADH, a commercially mixed
glycerol-3-phosphate dehydrogenase/trioseph-
osphate isomerase preparation and Aldolase
obtained from Boehringer Mannheim (Mu-
nich, Germany). The reaction was started by
addition of the NADH solution and the
enzymatic suspension. Changes in absorbance
at 365 nm were monitored for 15 minutes.
Glucose content
To assess glucose concentrations, approxi-
mately 150 mg of frozen intestinal samples
were homogenised in 0.6 ml of ice cold HCl
0.33 mol/l. The tissue homogenates were cen-
trifuged at 10 000 g for five minutes at 4°C.
Supernatant was used to measure glucose with
a commercial kit from Boehringer Mannheim.
GAPDH activity
GAPDH activity was determined in intestinal
tissues10 after homogenisation in ice cold buVer
consisting of 100 mM triethanol amine buVer
(pH 7.4), 1 mM EDTA, 2 mM dithiothreitol,
0.2 mM phenylmethylsulphonyl fluoride, leu-
peptin (1 µg/ml), and 10 mM GSH. The
homogenate was centrifuged at 10 000 g for 15
minutes. Supernatant was used as the cytosolic
fraction for determination of GAPDH activity.
Enzyme activity was measured using a mixture
containing 82.3 mM triethanol amine buVer
(pH 7.6), 1.1 mM ATP, 6.2 mM glycerate-3-
phosphate, 0.2 mM NADH, 0.9 mM EDTA,
2 mM MgSO4, and phosphoglycerate kinase
(13 units/ml). The reaction was started by
addition of the tissue sample and changes in
absorbance at 340 nm were monitored for five
minutes.
NO production
NO production in intestinal bowel was deter-
mined by tissue accumulation of nitrite and
nitrate using a modification of a method previ-
ously described.22 Briefly, frozen tissue speci-
mens were homogenised in 2 ml of phosphate
buVered saline (pH 7.4) at 4°C. Homogenates
(1 ml) were centrifuged at 100 000 g for 60
minutes, and 200 µl of supernatants were used
for subsequent measurement. Briefly, nitrate
was reduced to nitrite with 0.5 units of nitrate
Figure 1 Intestinal fructose-1,6-biphosphate (F16BP)
levels during the diVerent ischaemic periods (0, 2, 30, or 90
minutes) in the control, ischaemia (I), preconditioning
followed by sustained ischaemia (Prec+I), and
preconditioning followed by sustained ischaemia but with
prior addition of L-NAME (Prec+I+NAME) groups (A)
and in the control, control with previous administration of
L-NAME (Control+NAME), ischaemia (I), and
ischaemia with previous administration of the NO donor
spermine NONOate (I+NONOS) groups (B). *p<0.05 v
control;†p<0.05 v I.
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reductase in the presence of 50 µM NADPH
and 5 µM FAD. Excess NADPH was oxidised
in the presence of 0.2 mM pyruvate and 1 µg of
lactate dehydrogenase. Nitrite was determined
with Greiss reagent by adding 1 mM sulph-
anilic acid and 100 mM HCl. After five
minutes of incubation, tubes were centrifuged
and 150 µl of supernatant were transferred to a
96 well microtitre plate. After a first reading of
the absorbance at 595 nm,50 µl of naphthylene-
diamine were added. After 15 minutes of incu-
bation, absorbance was compared with the
standard NaNO2.
Protein concentration
Total protein concentration in homogenates
was determined using a commercial kit from
BioRad (Munich, Germany).
STATISTICAL ANALYSIS
Data are expressed as mean (SEM). Means of
diVerent groups were compared using one way
analysis of variance. The Student’s t test was
performed for evaluation of significant diVer-
ences between groups. Significant diVerences
were assumed when p<0.05.
Results
EFFECT OF PRECONDITIONING ON F16BP AND
GLUCOSE CONTENT DURING THE ISCHAEMIC
PERIOD
Figure 1A shows intestinal F16BP levels after
various ischaemic periods. F16BP concentra-
tions decreased as a function of sustained
ischaemic time. After two minutes of ischae-
mia, the ischaemic group (I) showed a
significant decrease in F16BP content com-
pared with the control group. In contrast, when
preconditioning was carried out before ischae-
mia (Prec+I), no significant decreases were
detected. Addition of L-NAME to precondi-
tioning rats (Prec+I+NAME) reversed this
eVect. After 30 and 90 minutes of sustained
ischaemia, all groups showed a significant
decrease in F16BP content compared with the
control group. However, preconditioned ani-
mals maintained a higher F16BP content than
the ischaemic group. L-NAME treatment
reversed these eVects. As shown in fig 1B, NO
administration to ischaemic rats (I+NONOS)
resulted in a significant increase in F16BP
content compared with the ischaemic group for
all ischaemic periods studied. However, admin-
istration of L-NAME to control rats
(Control+NAME) had no eVect on F16BP
levels.
Figure 2A shows intestinal levels of glucose
after the diVerent ischaemic periods. There was
a significant decrease in glucose for all
Figure 2 Intestinal glucose levels during the diVerent
ischaemic periods (0, 2, 30, or 90 minutes) in the control,
ischaemia (I), preconditioning followed by sustained
ischaemia (Prec+I), and preconditioning followed by
sustained ischaemia but with prior addition of L-NAME
(Prec+I+NAME) groups (A) and in the control, control
with previous administration of L-NAME
(Control+NAME), ischaemia (I), and ischaemia with
previous administration of the NO donor spermine
NONOate (I+NONOS) groups (B). *p<0.05 v control.
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Figure 3 GAPDH activity (U/mg protein) in the
intestine during the diVerent ischaemic periods (0, 2, 30, or
90 minutes) in the control, ischaemia (I), preconditioning
followed by sustained ischaemia (Prec+I), preconditioning
followed by sustained ischaemia but with prior addition of
L-NAME (Prec+I+NAME), preconditioning (P),
preconditioning with addition of L-NAME (P+NAME),
and preconditioning with addition of the iNOS specific
inhibitor (P+1400W) groups (A) and in the control,
control with previous administration of L-NAME
(Control+NAME), ischaemia (I), and ischaemia with
previous administration of the NO donor spermine
NONOate (I+NONOS) groups (B). *p<0.05 v control;
‡p<0.05 v preconditioned animals.
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ischaemic periods compared with the control
group. The decrease in glucose content was
significant after two minutes of ischaemia and
persisted for the other sustained ischaemic
periods. This eVect was apparent in all groups.
As shown in fig 2B, there were no variations in
this pattern when NO was administered to
ischaemic rats (I+NONOS) or L-NAME was
administered to control rats (Control+
NAME).
EFFECT OF NO ON GAPDH ACTIVITY BEFORE AND
DURING SUSTAINED ISCHAEMIA
As shown in fig 3A, preconditioning induced a
significant decrease in GAPDH activity com-
pared with the other groups. This decrease was
evident at the end of the preconditioning
period and was maintained after two minutes
of the subsequent sustained ischaemia.
L-NAME administration reversed this inhibi-
tion whereas addition of the iNOS inhibitor
1400W did not modify the decrease observed
during the preconditioned process. In the next
ischaemic periods (30 and 90 minutes), levels
of enzyme activity returned to control values,
indicating transient GAPDH inhibition in pre-
conditioned animals. Figure 3B shows that
administration of NO to ischaemic rats also
significantly decreased GAPDH activity com-
pared with the control group. Administration
of L-NAME to control rats did not aVect
GAPDH activity.
Figure 4A shows intestinal generation of
NO, evaluated as nitrite and nitrate produc-
tion. In accordance with the results in fig 3, NO
production increased significantly after the
preconditioning period. Administration of
1400W had no eVect on this accumulation,
whereas L-NAME reversed it. Administration
of this inhibitor did not have a significant eVect
on nitrite or nitrate levels in the control group.
Nitrite and nitrate production returned to
basal levels after two minutes of ischaemia (fig
4B). No diVerences were observed between the
ischaemic (I), preconditioned (Prec+I), or
Prec+I+NAME groups during any of the
ischaemic periods.
ROLE OF F16BP ON INTESTINAL PRECONDITIONING
Figure 5 shows protein content measured in
the intestinal perfusate. Protein release was sig-
nificantly increased in the ischaemic group
(I/R) at the end of sustained ischaemia (90
minutes) compared with the control group. It
was further increased five and 30 minutes after
reperfusion, reflecting progression of tissue
damage. In contrast, when preconditioning was
carried out before ischaemia (P+I/R), there
was a significant decrease compared with the
ischaemic group. When NO synthase was
inhibited by L-NAME (P+N+I/R), the eVect of
preconditioning with respect to protein release
Figure 4 Nitrate and nitrite tissue production in the
intestine in the following groups: control, control with
previous administration of L-NAME (C+NAME),
preconditioning (P: 10 minutes of ischaemia followed by 10
minutes of reperfusion), preconditioning with L-NAME
(P+NAME), and preconditioning with administration of
the iNOS specific inhibitor (P+1400W) (A), and control,
preconditioning (P), ischaemia (I), preconditioning
followed by sustained ischaemia (Prec+I), and
preconditioning followed by sustained ischaemia but with
prior addition of L-NAME (Prec+I+NAME) (B).
*p<0.05 v control.
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Figure 5 Profiles of protein release during the diVerent
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(B)) periods in the following groups: control,
preconditioning followed by the ischaemia/reperfusion period
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addition of L-NAME and with superfusion over the small
intestine of 5 mM of F16BP during the process
(P+N+I/R+F16BP), and preconditioning followed by the
ischaemia/reperfusion period but with prior addition of
L-NAME (P+N+I/R) (A) and control,
ischaemia/reperfusion with superfusion over the small
intestine of 5 mM of F16BP throughout the process
(I/R+F16BP), ischaemia with previous administration of
the NO donor spermine NONOate (I/R+NONOS), and
ischaemia/reperfusion (I/R) (B). *p<0.05 v control;
†p<0.05 vs I/R.
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was eliminated, showing a large increase in
protein release at the end of ischaemia and after
reperfusion. Addition of F16BP to this group
(P+N+I/R+F16BP) decreased protein release,
increasing it to an I/R group. This indicates
that F16BP protects against the deleterious
eVect of L-NAME.
In the same way, addition of F16BP to the
I/R group (I/R+F16BP) (fig 5B) also had a
protective eVect, similar to that of precondi-
tioning treatment. This was reflected by a simi-
lar pattern of protein release. These findings
indicate that F16BP exerts a protective eVect
against I/R injury. Administration of NO to the
ischaemic group (I/R+NONOS) also had a
beneficial eVect, showing a protein release pat-
tern similar to the I/R+F16BP group.
Figure 6 shows incorporation of F16BP
superfused in the intestine and mesentery.
F16BP levels were significantly higher than
those in the non-treated group at the end of
sustained ischaemia in the intestine as well as in
the mesentery.
Discussion
In contrast with other solid organ transplants,
progress in intestinal transplantation from an
experimental level to clinical practice has been
slow. But intestinal transplantation is possible
and is now, for some conditions, the most suit-
able therapeutic option. The small intestine is
one of the most sensitive tissues to the I/R syn-
drome, and hence is one of the leading factors
in small bowel rejection.23 24 Any mechanism
that could protect against I/R injury would
have a beneficial role in small bowel transplan-
tation.
This is the case with ischaemic precondition-
ing in which the tissue is rendered resistant to
the deleterious eVects of prolonged ischaemia
and reperfusion by previous exposure to brief
periods of vascular occlusion.5 25 As shown in
fig 5, preconditioning prevented the increase in
protein release in the perfusate (used here as a
marker of tissue injury) compared with the
ischaemic group, indicating the eVectiveness of
preconditioning in preventing intestinal
ischaemia/reperfusion damage. When NO gen-
eration was inhibited prior to preconditioning,
the protective eVect was eliminated. In con-
trast, when the NO donor was administered to
I/R animals, the protective eVect reappeared;
the rate of protein release was significantly
lower than that in the I/R group. These results
confirm our previously reported data which
suggested that part of the protective eVect of
preconditioning is dependent on NO genera-
tion.2
Weisbrodt and colleagues26 reported the
presence of both the inducible and constitutive
forms of NOS in the mouse and rat ileum but
only the constitutive form in the jejunum. In
this organ, NO has been shown to modulate
jejunal motility, blood flow, oxygen uptake,27–29
nutrient induced intestinal hyperaemia,30 epi-
thelial permeability,6 leucocyte adhesion to
post-capillary venules,31 and to maintain vascu-
lar integrity in endotoxin induced acute
intestinal damage in the rat.32
Previous studies have demonstrated that NO
can inhibit GAPDH, a critical enzyme in the
glycolytic pathway,8 9 indicating that NO may
be able to modulate anaerobic glycolysis by
inhibiting an important step in the pathway. We
recently demonstrated that NO generated dur-
ing preconditioning inhibits this enzyme in the
jejunum.10 In the same study we also reported
that iNOS was not involved in this eVect. Our
study confirms this finding. As shown in fig 3A,
administration of the specific iNOS inhibitor
1400W did not modify inhibited GAPDH
activity after preconditioning. In contrast,
L-NAME reversed this inhibition.
The profile of NO generation in the tissue
fits well with these results (fig 4A). NO gener-
ated during the preconditioning process de-
creased with addition of L-NAME. The
presence of 1400W could not inhibit NO gen-
eration, indicating that iNOS is not involved in
NO generation. Nitrite and nitrate tissue levels
returned to basal levels during sustained
ischaemia (fig 4B), indicating that NO release
is not maintained, as previously described.2
Therefore, this transient NO generation can
also inhibit transient GAPDH activity. As
shown in fig 3B, GAPDH inhibition is still pat-
ent at two minutes of preconditioning but dis-
appears in the other groups and throughout the
other ischaemic periods. Direct participation of
NO was also confirmed when NO was admin-
istered to the ischaemic group; in this case, it
maintained inhibition throughout the ischae-
mic process.
Alteration of GAPDH activity during glyco-
lysis may modify the formation rate of
glycolytic intermediates. One important glyco-
lytic intermediate that has a recognised eVect
as a tissue protector is F16BP, which acts by
facilitating metabolic recovery during hypoxia
and ischaemia.33 34 Our study has described a
mechanism by which this recognised endog-
enous protector may be accumulated as a con-
sequence of transient GAPDH inhibition.
When preconditioning was carried out be-
fore ischaemia (Prec+I/R), there were no
significant modifications in F16BP content
compared with control levels until 30 minutes
of ischaemia (fig 1). In contrast, in non-
preconditioned rats, significant decreases in
F16BP were already detected after just two
minutes of ischaemia. This suggests that
preconditioning can maintain basal F16BP
levels for longer. Moreover, F16BP modifica-
tions as a consequence of preconditioning are
dependent on NO generated in the precondi-
Figure 6 Intestinal fructose-1,6-biphosphate (F16BP)
levels incorporated in the intestine. I, ischaemia; I+F16BP,
ischaemia with superfusion over the small intestine of 5 mM
of F16BP throughout the process. †p<0.05 v I.
100
75
50
25
0
F1
6B
P
 (
n
m
o
l/g
) †
I + F16BP
Intestine
I
†
I + F16BP
Mesentery
I
Fructose-1,6-biphosphate in rat intestinal preconditioning 173
www.gutjnl.com
tioning period. This is supported by the fact
that administration of L-NAME to the precon-
ditioned groups resulted in F16BP levels simi-
lar to those obtained in the ischaemic group at
30 and 90 minutes. The direct relationship
between NO presence and F16BP accumula-
tion was also confirmed when NO was admin-
istered to ischaemic animals; in this case,
F16BP levels remained similar to controls in
spite of the ischaemic insult. The increase in
F16BP content in the preconditioned group at
the end of ischaemia may facilitate metabolic
recovery in the following reperfusion period,
possibly due to normal activity of GAPDH at
the end of ischaemia (see fig 3).
Figure 2 shows glucose content. The anoxia
period presented a stress that led to a rapid
decrease in glucose content in the first minutes
of ischaemia. Probably for this reason no
diVerences were detected in any of the groups.
Therefore, part of the protective eVect of
preconditioning is not due to an increase in
glucose content but may well be due to
accumulation of F16BP.
Another interesting finding was the lack of
eVect of L-NAME administration to control
animals (see figs 1–4). It is true that control
animals have physiological NO levels but these
basal levels are probably too low to aVect
GAPDH inhibition, and consequently F16BP
accumulation.
F16BP has a wide variety of protective
eVects independent of its action as a glycolytic
intermediate. It increases peristaltic activity,16 it
may inhibit neutrophil free radical produc-
tion,17 it maintains the correct XDH/XO
ratio,18 it stabilises intracellular calcium in the
hypoxic rat brain,19 and it has been used to
improve preservation solutions in renal trans-
plantation.20 In addition, the protective eVects
of exogenously administered F16BP have also
been observed in intestinal ischaemia16 and in
ileum muscle.14
To elucidate the eVect of F16BP under our
experimental conditions, we tested if F16BP
superfusion in ischaemic animals had any eVect
in the prevention of tissue injury. As shown in
fig 5A and 5B, I/R animals administrated
F16BP behaved in much the same way as those
subjected to preconditioning; hence F16BP
can diminish the damage caused by I/R injury.
Moreover, administration of F16BP to the
P+N+I/R group attenuated the deleterious
eVect of L-NAME treatment. In this last group,
F16BP improved damage but did not prevent it
completely. This could be explained as follows:
F16BP only helps to minimise the damage, and
in this group the absence of NO obstructed
complete improvement. This suggests that
irreversible NO inhibition by L-NAME prob-
ably stops essential cell functions and has
harmful consequences, independent of its
eVect on glycolysis.6 35 This damage is probably
irrecoverable, even with the beneficial eVect of
F16BP.
A number of reports have suggested a
protective role for exogenously applied F16BP
in tissues but many questions remain regarding
the ability of fructose to cross the cell
membrane. This is because F16BP has a neu-
tral pH by virtue of its two phosphates.
However, recent studies by Hardin and col-
leagues33 have demonstrated that F16BP can
cross the cell membrane in vascular smooth
muscle. They proposed possible mechanisms,
such as the use of a membrane carrier, an
increase in lipid solubility by binding with
other enzymes such as aldolase, passive perme-
ability of the membrane to F16BP, or endocy-
tosis of extracellular fluid containing F16BP.
This question was not specifically addressed
in our study. We propose a mechanism by
which F16BP is accumulated endogenously in
preconditioned rats. If preconditioning is
carried out before ischaemia, the intestine can
maintain high levels of this well known protec-
tor. This mechanism of protection from I/R
injury depends on NO synthesis. Nevertheless,
NO could oVer protection from I/R injury via
some other mechanism.
In summary, our study indicates that NO
generated during preconditioning inhibits the
glycolytic enzyme GAPDH, leading to NO
dependent accumulation of F16BP that exerts
a protective eVect. These data confirm that
preconditioning is an alternative protective
mechanism against I/R injury.
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